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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 

















• Investigation of incidence of 
SARS-CoV-2 infection in 
12,541 health care workers 
in UK 
• Presence of anti-spike or 
anti-nucleocapsid IgG 
antibodies was associated 
with a substantially reduced 
risk of SARS-CoV-2 















• Coronaviruses acquire 
substitutions more slowly 
than other RNA viruses, due 
to a proofreading 
polymerase 
• In the spike glycoprotein, 
recurrent deletions are 
found that overcome this 
slow substitution rate 
• Deletion variants arise in 
diverse genetic and 
geographic backgrounds 
and can transmit efficiently 
• Deletions frequently in the 
recurrent deletion regions 





• Progression of adaptations 
in immunocompromised 
patients remain to be 
resolved 
• Recurrence of adaptations 
in single patients, and on 
global scales highlights the 
importance of tracking and 
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ne (HCQ) in 3 
subgroups: (1) 
treating people 
with C19 on 
death and time to 











• HCQ for people 
infected with 
COVID-19 has 
little or no effect 







• There should be 








• Given these 
results, it is 
unlikely that the 




although this is 




infection could be 
carried out to 
give a clear 
answer 























on air or requiring 
oxygen therapy) 






usual standard of 
care alone versus 
usual standard of 
care plus 
tocilizumab at a 
dose of 400 mg 




• Primary outcome 
was 28-day 
mortality, 
assessed in the 
intention-to-treat 
population 










and other clinical 
outcomes 
• Benefits seen 
irrespective of the 
level of 
respiratory 
support and were 































• Phase 2 
randomised, 
open label trial of 
inhaled 
budesonide 
versus usual care 
in 146 adults 
within 7 days of 








used in long-term 
management of 
asthma and 




seven days of 
symptom onset 
reduced the need 
for urgent care, 
hospitalisation 
and recovery 



















The Lancet | 
Health Policy 
• Review of potential 
challenges to success in of 
COVID-19 production, 
affordability, allocations and 
deployment and a 
discussion of policy 
implications 
• Includes a dashboard to 
highlight key characteristics 
of 26 leading vaccine 
candidates with a traffic-
light system to signal the 
potential contributions of 
each candidate in achieving 
global vaccine immunity 
and important trade-offs in 
policy and implementation 
• Also 32-country survey from 
Oct to Dec 2020 on 
potential acceptance of 











ID for the 
digital 
yellow card 
CGD | Notes 
• A Covid Vaccine Certificate 
(CVC) is likely to become 
an important tool to help 
monitor and manage the 
rollout of vaccinations and 
in the recovery of national 
economies, facilitate safe 
movement of people across 
countries and rejuvenate 
tourism, important for many 
developing countries 
• These notes consider some 
lessons from rollout of 
identification systems 




• Low-cost, high-access 
approaches are essential to 
ensure that the digital and 
affordability gap does not 
widen, balancing Level of 














• A report on antibody and 
memory B cell responses in 
20 volunteers eight weeks 
after second vaccination 
with either Moderna or 
Pfizer-BioNTec vaccines 
• Modest effects of the 
mutations on viral sensitivity 
to plasma reflects 
polyclonal nature of 
neutralising antibodies 
• Mutations maybe emerging 
in response to immune 
selection in individuals with 
non-sterilising immunity 
• Plasma neutralising activity, 
and relative numbers of 
receptor binding domain-
specific memory B cells 
were equivalent to those 
recovering from natural 
infection  
• Authors conclude that 
monoclonal antibodies in 
clinical use should be 
tested against newly arising 
variants and that mRNA 
vaccines may need to be 
updated periodically to 





















• A literature review of the 
impacts of COVID-19 on 
mental well-being and the 
mental health and 
psychosocial support 
needs of adolescents in 
Viet Nam and Tanzania 
• COVID-19 has led to an 









anxiety, stress and 
depressive disorders with a 
particular impact from 
school closures and online 
learning 
• Older adolescents stress 
about examinations, their 
uncertain future and job 
prospects 
• Increased provision in 
services dedicated to 
combating domestic and 
online violence given 
increased exposure to 
abusive household 
conditions and online child 
abuse material  
• A variety of digital 
interventions were 
introduced in both 
countries, in response to 
restrictions on providing in-
person mental health 
services, reaching millions 
of adolescents globally. 
Key lessons must be learnt 
from this for post-Covid 
engagement and particular 
attention to accessibility 
Comments, Editorials, Opinions, Blogs, News  
Publication 
date 
Title/URL Journal | Article type 
15.02.2021 Covid-19: are cloth masks still effective? And other 
questions answered 
BMJ | News analysis 
13.02.2021 Tanzania refuses COVID-19 vaccines The Lancet | World 
Report 
12.02.2021 How ‘killer’ T cells could boost COVID immunity in face 
of new variants  
Nature | News 
12.02.2021 Genomic-informed pathogen surveillance in Africa: 
opportunities and challenges  
The Lancet Infectious 
Diseases | Personal view 
12.02.2021 Oxford University extends COVID-19 vaccine study to 
children 
University of Oxford | 
News 
12.02.2021 Can Covax deliver the vaccines much of the world 
needs? 
Financial Times | News 
12.02.2021 Priorities for the COVID-19 pandemic at the start of 
2021: statement of the Lancet COVID-19 Commission 
The Lancet | Comment 
12.02.2021 The hazards of medicine by tweet: the case of anti-
cytokine therapy for Covid-19 
Statnews 
11.02.2021 The COVID-19 exit strategy – why we need to aim low  The Lancet Infectious 
Diseases | Editorial 
11.02.2021 SARS-CoV-2 variants and ending the COVID-19 
pandemic 
The Lancet | Comment 
11.02.2021 SARS-CoV-2 variants and ending the COVID-19 
pandemic 
The Lancet | Comment 
10.02.2021 Redesigning health systems for global health security  The Lancet Global 
Health | Comment 
10.02.2021 Oxygen supplies and COVID-19 mortality in Africa The Lancet Respiratory 
Medicine | News 
10.02.2021 Drug trial that could improve respiratory recovery from 
COVID-19 now underway 
University of Oxford | 
News 
10.02.2021 The rich people’s virus? Latest reflection from 
Zimbabwe 
SSHAP | Blog 
10.02.2021 Expanding health product manufacturing in Africa: 
ideas for development finance institutions, procurers, 
and policymakers 
CGD | Blog 
10.02.2021 Release COVID-19 vaccine contracts CGD | Blog 
10.02.2021 How will COVID-19 impact our progress towards 
Universal Health Coverage  
CGD | Blog 
09.02.2021 Rapid coronavirus tests: a guide for the perplexed Nature | News 
09.02.2021 We can stop preventable COVID deaths by urgently 
prioritising medical oxygen and essential critical care  
CGD | Blog 
01.02.2021 COVID crisis is fueling food price rises for world’s 
poorest 
World Bank | Blog 
07.01.2021 What COVID-19 can mean for long-term inequality in 
developing countries 
World Bank | Blog 
03.02.2021 Put to the test: use of rapid testing technologies for 
covid-19 
BMJ | analysis 
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
10.02.2021 Interim 
recommendations 












• Interim guidance developed on 
the basis of WHO SAGE advice 
• Recommendation is two standard 
doses of ChAdOx1 nCoV-19 
administered at an 8-12 week 
interval in people aged 18 years 
and older 
• Priority to be given to health 
workers at high risk of exposure 
and older people, including those 
aged 65 or older 
• Further studies are required for 
persons living with HIV or auto-
immune or immunocompromised 
but may be vaccinated after 
receiving information and 
counselling 
Jan 2021 The inequality virus Oxfam | 
Report 
• Documenting how COVID-19 has 
affected different populations and 
parts of the world and impacts on 
those already-marginalised 
   
 
Dashboards & Trackers  












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 


















LSTM Stop TB 
Partnership 








  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of the 
WHO 




































































and Planning  
Norwegian 
Institute of Public 
Health 
    




JAMA Network Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE journals  Prevent 
Epidemics  
    
Our World in 
Data 





  Springer Nature       
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
  
Online learning & events 







for health workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 





starting 16 Nov 
  HIFA 
services during (and 
after) the pandemic 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 












online brief with Dr 
David Nabarro 














training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
  
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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